# Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

> **NCT00276159** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 6 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** 852A

## Key facts

- **NCT ID:** NCT00276159
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Drug was not available.
- **Last updated:** 2019-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276159, "Study of Immune Response Modifier in the Treatment of Hematologic Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00276159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*